The diagnosis and management of acute myeloid and acute lymphoblastic leukemia may be improved by the discovery on genetic analysis of several novel subgroups, US and European study findings suggest. Medscape Medical News

Related Links:

UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save…

Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profound therapeutic responses, resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors, regardless of histology. In contrast to solid tumors, the frequency of TRK fusions and the clinical effects of targeting TRK in hematologic malignancies are unknown. Here,…

Source: Journal of Clinical InvestigationCategory: Biomedical Science Authors: Source Type: research

z M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C
Abstract
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease. Currently classified as Grade II in Consensus criteria, upper gastrointestinal acute graft-versus-host disease is often treated with systemic immunosuppression. We reviewed the Center for International Blood and Marrow Transplant Research database to assess prognostic implications of upper gastrointestinal acute graft-versus-host disease in isolation or with other acute graf…

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

Langerhans cells (LCs) are a type of dendritic cell that characteristically express S100, CD1a, and langerin (CD207). Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of cells with the phenotype of activated LCs. Rarely, LCH may be associated with various hematologic neoplasms including acute lymphoblastic and myeloid leukemias, other clonal myeloid neoplasms, and lymphomas. Acute lymphoblastic leukemia is more often associated with LCH in children, whereas lymphoma and acute myeloid leukemia (AML) are more common in adults, which may reflect the frequency of these diseases in the respective populations.

CONCLUSIONS: Holistic patient support-specific activities and adapted protocols made a measurable impact on patient outcomes. High survival outcomes of patients have been achieved despite relatively few receiving salvage therapies or stem cell transplant.

Source: Indian Journal of CancerCategory: Cancer & Oncology Authors: Source Type: research

Conclusions:
IFD was an important cause of treatment related mortality in pediatric leukemia (odds ratio, 8.39). Protocolled use of computed tomography-chest and galactomannan-assay aided diagnosis (P

Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)–type primary th…

Source: BloodCategory: Hematology Authors: Tags: Pediatric Hematology, Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, CME article, Clinical Trials and Observations Source Type: research

Publication date: Available online 17 July 2018Source: The Lancet HaematologyAuthor(s): Mark P Little, Richard Wakeford, David Borrego, Benjamin French, Lydia B Zablotska, M Jacob Adams, Rodrigue Allodji, Florent de Vathaire, Choonsik Lee, Alina V Brenner, Jeremy S Miller, David Campbell, Mark S Pearce, Michele M Doody, Erik Holmberg, Marie Lundell, Siegal Sadetzki, Martha S Linet, Amy Berrington de GonzálezSummaryBackgroundSubstantial evidence links exposure to moderate or high doses of ionising radiation, particularly in childhood, with increased risk of leukaemia. The association of leukaemia with exposure to low-dose (

CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer …


Author: VJHemOnc
Added: 07/16/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Publication date: July 2018Source: The Journal of Molecular Diagnostics, Volume 20, Issue 4Author(s): Adrian G. Selim, Andrew S. MooreThe ability to sensitively monitor minimal residual disease (MRD) has played a key role in improving the management and outcomes for a number of leukemias, particularly acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast, MRD monitoring in acute myeloid leukemia (AML) has been limited by variable assay methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor genetic heterogeneity poses significant challenges for the identifi…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image